Fatal Rhabdomyolysis in a COVID-19 Patient on Rosuvastatin.
It is well-established by now that COVID-19 can have a wide variety of neuromuscular manifestations, including rhabdomyolysis. Weakness and elevated creatinine kinase (CK) have been documented as the initial presentation of COVID-19. Myopathy from statin use has also been well-established since the introduction of this class of medication, and the common pathologic mechanism of both entities may have been mitochondrial dysfunction. We present here the case of a COVID-19 patient on rosuvastatin who developed rhabdomyolysis with CK above 1,000,000 units/L. The patient did not present with any respiratory difficulty and responded poorly to treatment, resulting in his untimely demise. COVID-19 may have accentuated an otherwise survivable condition by means of extra stress on mitochondrial homeostasis. Understanding the actual mechanism will be important in the development and utilization of medications in the fight against COVID-19.
['Anklesaria|Zafia|Z|', 'Frankman|Jonathan|J|', 'Gordin|Jonathan|J|', 'Zhan|Jennifer|J|', 'Liu|Antonio K|AK|']
rhabdomyolysis covid-19 rosuvastatin